0001567619-20-015911.txt : 20200825 0001567619-20-015911.hdr.sgml : 20200825 20200824190620 ACCESSION NUMBER: 0001567619-20-015911 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200825 DATE AS OF CHANGE: 20200824 EFFECTIVENESS DATE: 20200825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NERVGEN PHARMA CORP. CENTRAL INDEX KEY: 0001751912 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-373998 FILM NUMBER: 201129107 BUSINESS ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 BUSINESS PHONE: 6047225361 MAIL ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 D 1 primary_doc.xml X0708 D LIVE 0001751912 NERVGEN PHARMA CORP. SUITE 1703, THREE BENTALL CENTRE 595 BURRARD STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V7X 1J1 604-880-6056 BRITISH COLUMBIA, CANADA None None Corporation true 2017 Bill Radvak Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Brian Bayley Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Michael Abrams Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Harold Punnett Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Paul Brennan Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Director Lloyd Mackenzie Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer William Adams Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Amy Franke Suite 1703, Three Bentall Centre 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Other Decline to Disclose 06b false 2020-08-10 true true true true Units consist of one common share and one common share purchase warrant, exercisable at CAD$2.40 per share for a period of 24 months. false 0 Arcadia Securities, LLC 44656 None None 1370 Avenue of the Americas 29th FL New York NY NEW YORK 10019 AL ALABAMA NJ NEW JERSEY NY NEW YORK WY WYOMING false Haywood Securities Inc. None Haywood Securities (USA) Inc. 42072 200 Burrard Street Suite 700 Vancouver A1 BRITISH COLUMBIA, CANADA V6C 3L6 CA CALIFORNIA GA GEORGIA IL ILLINOIS MA MASSACHUSETTS NY NEW YORK PA PENNSYLVANIA TX TEXAS false 5357419 2194379 3163040 (c) represents the maximum potential exercise price of warrants. Subscriptions paid in Canadian currency converted to US dollars at CAD$1.3354 = USD$1.00. false 16 153607 true 0 In addition to the cash compensation above, the agents received 117,221 warrants in connection with the U.S. sales; each warrant is exercisable for one share of common stock at C$1.75 for 24 months. 0 false NERVGEN PHARMA CORP. /s/ William Adams William Adams Chief Financial Officer 2020-08-21